MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata

NCT05205070 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2022-05-10

No results posted yet for this study

Summary

Efficacy and safety of rosnilimab (ANB030) in subjects with moderate-to-severe Alopecia Areata

Conditions

Interventions

BIOLOGICAL

Rosnilimab

humanized monoclonal antibody

BIOLOGICAL

Placebo

Placebo solution

Sponsors & Collaborators

  • AnaptysBio, Inc.

    lead INDUSTRY

Principal Investigators

  • Bruce Randazzo, MD · AnaptysBio, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-22
Primary Completion
2023-01-19
Completion
2023-03-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05205070 on ClinicalTrials.gov